– USA, MA – PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of Laurie Keating as Chair of its Board of Directors, replacing Dr. Ramin Farzaneh-Far who will continue in his current role as acting CMO.
“We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of the executive teams of two Boston biotechs that have transitioned from preclinical to successful commercial companies. We look forward to her strategic contributions and guidance as we continue to grow and build PepGen into a leading oligonucleotide therapies company focused on serious genetic disorders,” said CEO, Dr. James McArthur.
About Laurie Keating
In addition to her role on the PepGen Board of Directors, Laurie Keating also serves as a Director of Immuneering Corp (Nasdaq: IMRX) and Imago Biosciences (Nasdaq: IMGO) and has served for more than ten years on the Board of MassBio. Laurie previously served as the Executive Vice President, General Counsel, and Corporate Secretary of Alnylam Pharmaceuticals. In this role, she led global government affairs, legal, IP, litigation, and compliance, and advised the Board on financing and strategic collaborations, governance, and corporate strategy. Before Alnylam, she served as SVP, General Counsel, and Corporate Secretary of Millennium Pharmaceuticals, a commercial-stage company that was later acquired by Takeda. At Millennium, Laurie led the global Legal, Intellectual Property, Corporate Quality, and Compliance groups. Before Millennium, Laurie was founding CEO and a director of Hydra Biosciences. Her contributions and executive leadership at public high technology companies earlier in her career led to her being named one of the 45 most influential in-house lawyers in the U.S. under the age of 45.
“I am thrilled to be joining PepGen as the new Chair of the Board of Directors. I look forward to guiding the company’s development and supporting the leadership team as they seek to transform the lives of patients with innovative new treatment options for severe neuromuscular and neurologic diseases,” said Laurie Keating.
Laurie earned her bachelor’s degree in Economics from the University of California at Berkeley, and her JD from the University of California, Hastings College of the Law.
About PepGen
PepGen, Inc. is a biotechnology company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases. PepGen’s proprietary Enhanced Delivery Oligonucleotides are designed to target the underlying causes of rare diseases safely and effectively such as Duchenne muscular dystrophy and myotonic dystrophy type 1. In preclinical studies, PepGen’s enhanced delivery peptides demonstrated success in cell penetration and delivery of therapeutic candidates to multiple tissue types, including cardiac tissue. PepGen was founded by leading neurology researchers in Oxford, UK and is backed by a strong syndicate of investors including RA Capital Management, Oxford Science Enterprises, and others. The company is headquartered in Boston, Mass.
For more information: https://pepgen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
